Chiron Capital Management’s Amedisys AMED Stock Holding History

Chiron Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2	Closed	–	–	96
2020 Q3	$0	Buy	+2	New	+$455	﹤0.01%	496

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Chiron Capital Management's AMED Position: Q4 2020 in Review

Chiron Capital Management sold out of Amedisys (AMED) in Q4 2020, closing a stake of 2 shares.

Chiron Capital Management first reported a position in AMED in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 396 funds tracked by Wall St. Rank hold AMED as of Q4 2020.

Chiron Capital Management reported no remaining Amedisys position as of Q4 2020 after selling out during the quarter.
Chiron Capital Management sold 2 Amedisys shares in Q4 2020.
Chiron Capital Management first reported a position in Amedisys in Q3 2020 and held it in 1 quarter.
Chiron Capital Management's Amedisys position peaked at $0 in Q3 2020.
396 funds tracked by Wall St. Rank held Amedisys as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.